Shares of GSK plc (LON:GSK – Get Free Report) have received a consensus recommendation of “Hold” from the eight research firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is GBX 2,145.
Several research firms recently commented on GSK. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,500 target price on shares of GSK in a research note on Tuesday, October 20th. Royal Bank Of Canada assumed coverage on GSK in a research note on Tuesday, September 8th. They issued a “sector perform” rating and a GBX 1,975 price target on the stock. Deutsche Bank restated a “hold” rating and set a GBX 2,000 price target on shares of GSK in a report on Tuesday, November 10th. Finally, Berenberg Bank reaffirmed a “buy” rating and set a GBX 2,200 price objective on shares of GSK in a research report on Tuesday, November 3rd.
Read Our Latest Stock Analysis on GSK
GSK Stock Performance
GSK (LON:GSK – Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The company reported GBX 54.60 earnings per share for the quarter. The firm had revenue of GBX 888.70 billion during the quarter. GSK had a return on equity of 24.64% and a net margin of 12.97%. As a group, analysts predict that GSK will post 175.98 EPS for the current year.
Insiders Place Their Bets
In related news, insider Jonathan Symonds purchased 1,500 shares of the firm’s stock in a transaction on Friday, September 18th. The stock was purchased at an average cost of GBX 1,881 per share, with a total value of £28,215. Also, insider Anne Beal acquired 637 shares of the company’s stock in a transaction dated Friday, September 18th. The shares were bought at an average price of GBX 4,985 per share, for a total transaction of £31,754.45. Insiders acquired 2,151 shares of company stock valued at $6,021,921 over the last 90 days. Corporate insiders own 0.20% of the company’s stock.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
Read More
- Five stocks we like better than GSK
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
